Supplementary Methods S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Ahmad A. Tarhini; Alyssa Obermayer; Sandra J. Lee; William A. LaFramboise; F. Stephen Hodi; Arivarasan Karunamurthy; Islam Eljilany; Dung‐Tsa Chen; Patrick Hwu; Issam El Naqa; Howard Streicher; Vernon K. Sondak; Walter J. Storkus; Lisa H. Butterfield; Timothy I. Shaw; John M. Kirkwood

doi:10.1158/1078-0432.29760683

August 1, 2025

Supplementary Methods S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: The approach identifies robust biomarkers that enhance predictive power for immunotherapy benefits in melanoma.
KEY EVIDENCE: Gene expression profiling and multiplex cytokine analysis are pivotal in determining treatment outcomes.
APPROACH: Utilized various methods including flow cytometry and survival analysis for comprehensive assessment.
SIGNIFICANCE: This work advances personalized treatment strategies in high-risk melanoma cases, aiming to improve patient outcomes.

Implication

Gene expression profiling and cytokine analysis improve biomarker prediction in melanoma, suggesting enhanced immunotherapy outcomes.

Abstract

Supplementary Methods S1. Gene Expression Profiling (GEP), Peripheral Blood, Multiplex Serum Cytokine Analysis, Multicolor Flow Cytometry, Survival Analysis, LASSO Signature Training and Testing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tarhini et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0204 https://doi.org/10.1158/1078-0432.29760683

View at Publisher

Ask AI

Bookmark

Share

Supplementary Methods S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Methods S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers